DOI: https://doi.org/10.7203/metode.12.18411

Medications against drugs: Development of medications to prevent and treat substance use disorders


Abstract


Substance use disorder (SUD) is a significant public health concern. Unfortunately, there are few safe and effective medications to treat SUD and efficacy is suboptimal. There are important financial and scientific obstacles to develop new compounds, but recent advances in the discovery of new brain receptors and neurocircuits are offering opportunities to develop new pharmacotherapies. A systematic scientific approach to develop medications is required to demonstrate their safety and efficacy, bring it to market, and prescribe it to patients. The purpose of this manuscript is to provide a general overview of the challenges and opportunities in medications development for SUD, describe the phased approach of this development, the medications approved, and those that appear most promising.


Keywords


medications development; substance use disorders; treatment; clinical trials

References


Banks, M. L., Townsend, E. A., & Negus, S. S. (2019). Testing the 10 most wanted: A preclinical algorithm to screen candidate opioid use disorder medications. Neuropsychopharmacology, 44(6), 1011–1012. https://doi.org/10.1038/s41386-019-0336-5

Coffa, D., & Snyder, H. (2019). Opioid use disorder: Medical treatment options. American Family Physician, 100(7), 416–425.

Collins, F. S., Koroshetz, W. J., & Volkow, N. D. (2018). Helping to end addiction over the long-term: The research plan for the NIH HEAL Initiative. Jama, 320(2), 129–130. https://doi.org/10.1001/jama.2018.8826

Epstein, D. H., Preston, K. L., & Jasinski, D. R. (2006). Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: Lessons from tramadol. Biological Psychology, 73(1), 90–99. https://doi.org/10.1016/j.biopsycho.2006.01.010

Johnson, D. N., & Vocci, F. J. (1993). Medications development at the National Institute on Drug Abuse: focus on cocaine. NIDA research monograph, 135, 57–70.

Kiluk, B. D., Carroll, K. M., Duhig, A., Falk, D. E., Kampman, K., Lai, S., Litten, R. Z., McCann, D. J., Montoya, I. D., Preston, K. L., Skolnick, P., Weisner, C., Woody, G., Chandler, R., Detke, M. J., Dunn, K., Dworkin, R. H., Fertig, J., Gewandter, J., … Strain, E. C. (2016). Measures of outcome for stimulant trials: ACTTION recommendations and research agenda. Drug and Alcohol Dependence, 158, 1–7. https://doi.org/10.1016/j.drugalcdep.2015.11.004

Kleykamp, B. A., De Santis, M., Dworkin, R. H., Huhn, A. S., Kampman, K. M., Montoya, I. D., Preston, K. L., Ramey, T., Smith, S. M., Turk, D. C., Walsh, R., Weiss, R. D., & Strain, E. C. (2019). Craving and opioid use disorder: A scoping review. Drug and Alcohol Dependence, 205, 107639. https://doi.org/10.1016/j.drugalcdep.2019.107639

Kreek, M. J., Reed, B., & Butelman, E. R. (2019). Current status of opioid addiction treatment and related preclinical research. Science Advances, 5(10), eaax9140. https://doi.org/10.1126/sciadv.aax9140

Loflin, M. J. E., Kiluk, B. D., Huestis, M. A., Aklin, W. M., Budney, A. J., Carroll, K. M., D'Souza, D. C., Dworkin, R. H., Gray, K. M., Hasin, D. S., Lee, D. C., Le Foll, B., Levin, F. R., Lile, J. A., Mason, B. J., McRae-Clark, A. L., Montoya, I., Peters, E. N., Ramey, T., … Strain, E. C. (2020). The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda. Drug and Alcohol Dependence, 212, 107993. https://doi.org/10.1016/j.drugalcdep.2020.107993

Montoya, I. D. (2012). Advances in the development of biologics to treat drug addictions and overdose. Adicciones, 24(2), 95–103. https://doi.org/10.20882/adicciones.101

Montoya, I. D. (Ed.) (2016). Biologics to treat substance use disorders. Springer International Publishing. https://doi.org/10.1007/978-3-319-23150-1

Montoya, I. D., Hess, J. M., Preston, K. L., & Gorelick, D. A. (1995). A model for pharmacological research-treatment of cocaine dependence. Journal of Substance Abuse and Treatment, 12(6), 415–421. https://doi.org/10.1016/0740-5472(95)02017-9

Montoya, I. D., & McCann, D. J. (2010). Drugs of abuse: management of intoxication and antidotes. In A. Luch (Ed.) Molecular, clinical and Environmental Toxicology. Experientia Supplementum, vol 100, (pp. 519–541). Birkhäuser Basel. https://doi.org/10.1007/978-3-7643-8338-1_15

Montoya, I. D., & Weiss, S. (Eds.) (2018). Cannabis use disorders. Springer International Publishing. https://doi.org/10.1007/978-3-319-90365-1

Rasmussen, K., White D. A., Acri, J. B. (2019). NIDA's medication development priorities in response to the Opioid Crisis: ten most wanted. Neuropsychopharmacology, 44(4), 657–659. doi: https://doi.org/10.1038/s41386-018-0292-5

Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., Wood, E., & Fairbairn, N. (2020). Treatment of stimulant use disorder: A systematic review of reviews. PLoS One, 15(6), e0234809. https://doi.org/10.1371/journal.pone.0234809

SAMHSA. (2019). Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Center for Behavioral Health Statistics and Quality. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data

Skolnick, P., & Volkow, N. D. (2012). Addiction therapeutics: obstacles and opportunities. Biological Psychiatry, 72(11), 890–891. https://doi.org/10.1016/j.biopsych.2012.08.004

Vandrey, R., & Haney, M. (2009). Pharmacotherapy for cannabis dependence: How close are we? CNS Drugs, 23(7), 543–553. https://doi.org/10.2165/00023210-200923070-00001

Vocci, F., & Ling, W. (2005). Medications development: Successes and challenges. Pharmacology and Therapeutics, 108(1), 94–108. https://doi.org/10.1016/j.pharmthera.2005.06.010

Volkow, N. D. (2020). Collision of the COVID-19 and addiction epidemics. Annals of Internal Medicine, 173(1), 61–62. https://doi.org/10.7326/m20-1212

Yu, E., Miotto, K., Akerele, E., Montgomery, A., Elkashef, A., Walsh, R., Montoya, I., Fischman, M. W., Collins, J., McSherry, F., Boardman, K., Davies, D. K., O'Brien, C. P., Ling, W., Kleber, H., & Herman, B. H. (2008). A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug and Alcohol Dependence, 97(1-2), 158–168. https://doi.org/10.1016/j.drugalcdep.2008.04.002







Creative Commons License
Texts in the journal are –unless otherwise indicated– published under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License

____________________________________________________________________________________________________________________